VX-670

Pipeline

Status by Indication[3][1]

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Myotonic Dystrophy Type 1 (DM1)2 trials

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I

Enrolling by invitation·Vertex Pharmaceuticals·Phase 2·NCT06926621·44 enrolled

A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1

Active, not recruiting·Vertex Pharmaceuticals·Preclinical·NCT06185764·47 enrolled

Details

Drug Info

Related News